Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Endostar Infusion Methods in Advanced NSCLC
NCT04942301Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Time to maximum concentration, Maximum plasma concentration and 8 more. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04942301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942301.